Centre d'Investigation Clinique de Lyon, Service d’Explorations Fonctionnelles Cardiovasculaires, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
Circ Res. 2013 Aug 2;113(4):439-50. doi: 10.1161/CIRCRESAHA.113.300764.
Myocardial conditioning is an endogenous cardioprotective phenomenon that profoundly limits infarct size in experimental models. The current challenge is to translate this paradigm from the laboratory to the clinic. Accordingly, our goal in this review is to provide a critical summary of the progress toward, opportunities for, and caveats to, the successful clinical translation of postconditioning and remote conditioning, the 2 conditioning strategies considered to have the broadest applicability for real-world patient care. In the majority of phase II studies published to date, postconditioning evoked a ≈35% reduction of infarct size in ST-segment-elevation myocardial infarction patients. Essential criteria for the successful implementation of postconditioning include the appropriate choice of patients (ie, those with large risk regions and negligible collateral flow), timely application of the postconditioning stimulus (immediately on reperfusion), together with proper choice of end points (infarct size, with concomitant assessment of risk region). Remote conditioning has been applied in planned ischemic events (including cardiac surgery and elective percutaneous coronary intervention) and in ST-segment-elevation myocardial infarction patients during hospital transport. Controversies with regard to efficacy have emerged, particularly among surgical trials. These disparate outcomes in all likelihood reflect the remarkable heterogeneity within and among studies, together with a deficit in our understanding of the impact of these variations on the infarct-sparing effect of remote conditioning. Ongoing phase III trials will provide critical insight into the future role of postconditioning and remote conditioning as clinically relevant cardioprotective strategies.
心肌预处理是一种内源性的心脏保护现象,可显著限制实验模型中的梗塞面积。目前的挑战是将这一范例从实验室转化为临床。因此,我们在这篇综述中的目标是批判性地总结向临床转化的进展、机会和注意事项,即两种预处理策略,它们被认为对现实患者护理具有最广泛的适用性。在迄今为止发表的大多数 II 期研究中,预处理可使 ST 段抬高型心肌梗死患者的梗塞面积减少约 35%。成功实施预处理的基本标准包括适当选择患者(即那些有大风险区域和几乎没有侧支血流的患者)、及时应用预处理刺激(在再灌注时立即应用),以及适当选择终点(梗塞面积,同时评估风险区域)。远程预处理已应用于计划的缺血事件(包括心脏手术和选择性经皮冠状动脉介入治疗)以及在医院转运期间的 ST 段抬高型心肌梗死患者中。在有效性方面出现了争议,尤其是在外科试验中。这些不同的结果很可能反映了研究内和研究间的显著异质性,以及我们对这些变化对远程预处理的梗塞保护效果的影响的理解不足。正在进行的 III 期试验将为预处理和远程预处理作为临床相关的心脏保护策略的未来作用提供关键的见解。